AiBtl BioPharma, ABVC BioPharma's subsidiary, has acquired precision medicine manufacturer TT Life Company by purchasing 1.66 million shares priced at USD 5.00 per share, valuing the deal at around USD 8.33 million. This also includes acquiring the Malaysian import trading company, direct sales company, and Taiwanese direct sales company.

The acquisition is anticipated to leverage TT Life Company's expertise in product design and manufacturing to generate synergies across R&D, manufacturing, distribution, and financial capabilities, potentially enabling AiBtl to launch a wide array of AI-driven precision medicine.

AiBtl BioPharma is a biopharmaceutical company engaged in the development of novel therapies for central nervous system disorders, including major depressive disorder (MDD) and ADHD. The company's approach involves utilizing plant-based norepinephrine transporter inhibitors, currently in clinical development stages. One drug is in Phase IIb trials, and another has completed Phase II and is moving towards Phase III. AiBtl BioPharma operates from the United States and has significant activities in Asia, including clinical trials conducted in Cambodia, Thailand, and Japan.